Lung Cell Protein Triggers a Dangerous Immune Response
|
By LabMedica International staff writers Posted on 23 Aug 2016 |

Image: Teneema Kuriakose, Ph.D., a postdoctoral research associate, and Thirumala-Devi Kanneganti, Ph.D. Immunologists have identified the protein trigger in the body’s quick-reaction innate immune system that specifically recognizes the influenza virus in infected cells and triggers their death (Photo courtesy of St. Jude Children’s Research Hospital).
A protein in the cytoplasm of lung cells helps protect against viral infection, but following invasion by the influenza virus, the same protein stimulates the immune system to overact, which can lead to inflammation or pneumonia.
Individuals infected with influenza become ill not only because of the presence of virus but also because of the inflammatory immune response triggered by reaction to the virus.
The Z-DNA binding protein 1 (ZBP1, also known as DNA-dependent activator of IFN regulatory factors) gene encodes a Z-DNA binding protein. Z-DNA formation is a dynamic process, largely controlled by the amount of supercoiling. ZBP1 recognizes DNA in the cytoplasm as an antiviral mechanism. Viral life cycles often include steps where DNA is exposed in the cytoplasm. DNA is normally contained in the nucleus of a cell, and therefore cells use proteins like ZBP1 as an indicator of a viral infection. Once ZBP1 is activated, it increases the production of antiviral cytokines such as interferon-beta (INF-beta).
Investigators at St. Jude Children's Research Hospital (Memphis, TN, USA) initially demonstrated that ZBP1-mediated sensing of the influenza A virus (IAV) proteins NP and PB1 triggered cell death and inflammatory responses.
In order to further clarify the role of ZPB1 in flu infection, they used genetic engineering techniques to create a line of mice that lacked the ZBP1 gene.
The investigators reported in the August 12, 2016, online edition of the journal Science Immunology that mice lacking ZBP1 showed an increased viral load and delayed recovery. On the other hand, these mice had decreased inflammation and less epithelial damage than control animals.
"Our discovery was totally unexpected," said senior author Dr. Thirumala-Devi Kanneganti, an immunologist at St. Jude Children's Research Hospital. "We never thought we would actually identify this molecule to be important in influenza viral infection, because there is no DNA stage in the influenza life cycle. ZBP1 does an amazing job of killing off infected cells. But it would be very useful to modulate ZBP1 in later stages of the infection, when the uncontrolled inflammation causes damage."
"Since the pathology that we saw in the mice matches what is seen in humans, we will now explore translating these findings to humans," said Dr. Kanneganti. "If we can somehow modulate the activation of this pathway, that will help to decrease the exaggerated inflammatory response that causes mortality during influenza infection. We have shown that these molecules are important in viral infections, but now we want to test their role in other inflammatory conditions. ZBP1 is likely not dedicated to attacking only the influenza virus. Maybe it also plays other roles, and if we fully understand those roles, we can learn how to manipulate immune responses."
Related Links:
St. Jude Children's Research Hospital
Individuals infected with influenza become ill not only because of the presence of virus but also because of the inflammatory immune response triggered by reaction to the virus.
The Z-DNA binding protein 1 (ZBP1, also known as DNA-dependent activator of IFN regulatory factors) gene encodes a Z-DNA binding protein. Z-DNA formation is a dynamic process, largely controlled by the amount of supercoiling. ZBP1 recognizes DNA in the cytoplasm as an antiviral mechanism. Viral life cycles often include steps where DNA is exposed in the cytoplasm. DNA is normally contained in the nucleus of a cell, and therefore cells use proteins like ZBP1 as an indicator of a viral infection. Once ZBP1 is activated, it increases the production of antiviral cytokines such as interferon-beta (INF-beta).
Investigators at St. Jude Children's Research Hospital (Memphis, TN, USA) initially demonstrated that ZBP1-mediated sensing of the influenza A virus (IAV) proteins NP and PB1 triggered cell death and inflammatory responses.
In order to further clarify the role of ZPB1 in flu infection, they used genetic engineering techniques to create a line of mice that lacked the ZBP1 gene.
The investigators reported in the August 12, 2016, online edition of the journal Science Immunology that mice lacking ZBP1 showed an increased viral load and delayed recovery. On the other hand, these mice had decreased inflammation and less epithelial damage than control animals.
"Our discovery was totally unexpected," said senior author Dr. Thirumala-Devi Kanneganti, an immunologist at St. Jude Children's Research Hospital. "We never thought we would actually identify this molecule to be important in influenza viral infection, because there is no DNA stage in the influenza life cycle. ZBP1 does an amazing job of killing off infected cells. But it would be very useful to modulate ZBP1 in later stages of the infection, when the uncontrolled inflammation causes damage."
"Since the pathology that we saw in the mice matches what is seen in humans, we will now explore translating these findings to humans," said Dr. Kanneganti. "If we can somehow modulate the activation of this pathway, that will help to decrease the exaggerated inflammatory response that causes mortality during influenza infection. We have shown that these molecules are important in viral infections, but now we want to test their role in other inflammatory conditions. ZBP1 is likely not dedicated to attacking only the influenza virus. Maybe it also plays other roles, and if we fully understand those roles, we can learn how to manipulate immune responses."
Related Links:
St. Jude Children's Research Hospital
Latest BioResearch News
- AI-Powered Genome Mapping Reveals New Layer of Alzheimer’s Disease Biology
- Genetic Variations Reveal Mechanisms Behind Sudden Cardiac Death Risk
- Immune Biomarkers Support Early Risk Stratification in Oral Precancer
- Global Genetic Map Identifies Regional Parkinson’s Variants to Support Diagnostics
- Breakthrough Genetic Map Advances Understanding of Bone Disorders
- Study Identifies Hereditary Subtype of Aggressive Prostate Cancer
- Gene Variants Linked to Pollution-Exacerbated Asthma
- Single-Cell Analysis Mapping Links Inflammation Response to Acute Myeloid Leukemia
- Study Reveals New Insights into Rare Blood Cancer Development
- New Findings Clarify Molecular Drivers of Rare Small Intestinal Cancer
- Lung Cancer Study Reveals Cellular Program Behind Therapy Resistance
- Tumor Genome Marker May Predict Treatment Benefit in Pediatric Cancers
- Lysosomal Gene Defect Linked to Severe Childhood Brain Disorders
- Genetic Testing Identifies Greater Inherited Sudden Cardiac Arrest Risk in Younger Individuals
- Hidden 'Jumping Gene' Variant Linked to Higher Pancreatic Cancer Risk
- Common White Blood Cells Produce Schizophrenia-Linked Protein
Channels
Clinical Chemistry
view channel
Blood Protein Panel Predicts Timing of ALS Symptom Onset
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease in which clinical signs often emerge only after substantial motor neuron injury has already occurred, complicating timely intervention.... Read more
Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers
Venous blood draws can be challenging in patients with difficult veins, needle phobia, or limited blood volume, and they can slow collection in busy services. Core laboratories also face pressure to expand... Read moreMolecular Diagnostics
view channel
Genomic Fingerprints Reveal Early Chemotherapy Resistance in Childhood Cancer
Chemotherapy remains central to treating childhood cancers, yet its toxic effects can injure healthy tissues, and some tumors later relapse or spread. Clinicians have lacked early molecular markers that... Read more
Blood Gene Expression Fluctuates More Than Expected Over Time
Blood-based gene expression is widely used to explore disease biology, but temporal variability can complicate interpretation of single time-point measurements. Seasonal shifts, time of day, and subclinical... Read more
Genomic Test Helps Early Breast Cancer Patients Avoid Chemotherapy
Adjuvant chemotherapy decisions in early breast cancer can expose many patients to toxicities without clear benefit when clinical factors alone do not precisely predict recurrence risk. Clinicians therefore... Read more
Residual Disease Test Predicts Merkel Cell Carcinoma Recurrence Earlier Than Antibody Assay
Merkel cell carcinoma is a rare, aggressive skin cancer with a substantial risk of relapse, occurring in about 40% of patients. Surveillance remains challenging because widely used serologic monitoring... Read moreHematology
view channel
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
imal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately 202,000... Read more
New Marker Helps Detect Aggressive Multiple Myeloma Earlier
Multiple myeloma is an incurable malignancy of plasma cells and the second most common blood cancer worldwide, with more than 188,000 new cases each year. Although therapies have advanced, most patients... Read moreImmunology
view channel
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
Testing for tuberculosis remains a persistent global need, with demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies, and public health programs.... Read more
Expanded Diagnostics and Therapies Target Rising Gonorrhea Resistance
Drug-resistant Neisseria gonorrhoeae is straining current treatment protocols and elevating the risk of complications across sexual health services. More than 500,000 cases are reported each year in the... Read morePathology
view channel
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read more
AI Digital Pathology Platform Standardizes IHC Scoring in Breast Cancer
Breast cancer diagnostic workflows increasingly depend on accurate quantification of immunohistochemical biomarkers to guide therapy selection, yet manual scoring can be variable and time-consuming.... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Collaboration Advances Sputum-Based Diagnostics for Asthma and COPD
Asthma and chronic obstructive pulmonary disease are highly prevalent inflammatory airway conditions, affecting more than 40 million Americans and more than 650 million people worldwide.... Read more








